Vestal Point Capital LP Sells 725,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Vestal Point Capital LP lowered its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 41.4% in the third quarter, Holdings Channel reports. The firm owned 1,025,000 shares of the company’s stock after selling 725,000 shares during the quarter. Vestal Point Capital LP’s holdings in iTeos Therapeutics were worth $10,465,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ITOS. Vanguard Group Inc. raised its stake in iTeos Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after acquiring an additional 9,660 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after purchasing an additional 117,159 shares during the period. Candriam S.C.A. bought a new stake in iTeos Therapeutics in the 2nd quarter valued at $7,558,000. Algert Global LLC increased its position in iTeos Therapeutics by 92.0% during the 3rd quarter. Algert Global LLC now owns 256,139 shares of the company’s stock worth $2,615,000 after buying an additional 122,730 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in iTeos Therapeutics by 3.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock worth $2,268,000 after acquiring an additional 8,397 shares during the period. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ITOS. Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company. JPMorgan Chase & Co. reduced their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a report on Friday, November 15th. Finally, Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Tuesday, November 12th.

iTeos Therapeutics Stock Performance

NASDAQ ITOS opened at $8.54 on Friday. iTeos Therapeutics, Inc. has a twelve month low of $7.54 and a twelve month high of $18.75. The stock has a fifty day simple moving average of $9.18 and a 200 day simple moving average of $13.70.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Research analysts predict that iTeos Therapeutics, Inc. will post -3.46 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Matthew Gall acquired 5,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the transaction, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 12.50% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.